Key result
The combined detection of serum NT-pro-BNP, IGFBP-7, and CTRP12 demonstrated high predictive efficacy for major adverse cardiovascular events in patients with chronic heart failure, yielding an AUC of 0.961.
Why the study?
To investigate serum NT-pro-BNP, IGFBP-7, and CTRP12 levels and their significance in patients with chronic heart failure.
Do serum levels of NT-pro-BNP, IGFBP-7, and CTRP12 predict major adverse cardiovascular events in patients with chronic heart failure?
Population
116 CHF patients and 64 healthy controls
Comparison
CHF patients across NYHA grades II-IV vs healthy controls
Design
Observational case-control study
Authors
Loading...
NT-pro-BNP and IGFBP-7 elevations with CTRP12 reduction track CHF severity and MACE risk; leaves open incremental value over standard markers.
Observational (n=180)
No
Do serum levels of NT-pro-BNP, IGFBP-7, and CTRP12 predict major adverse cardiovascular events in patients with chronic heart failure?
Effect estimate: AUC 0.961 (95% CI 0.908-0.988)
p-value: p=<0.001
Fan et al. (2025) conducted an observational in Chronic heart failure (n=180). Combined serum NT-pro-BNP, IGFBP-7, and CTRP12 levels vs. Individual biomarker levels was evaluated on Prediction of Major Adverse Cardiovascular Events (MACE) (AUC 0.961, 95% CI 0.908-0.988, p=<0.001). The combined detection of serum NT-pro-BNP, IGFBP-7, and CTRP12 demonstrated high predictive efficacy for major adverse cardiovascular events in patients with chronic heart failure, yielding an AUC of 0.961.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: